Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 SalvaRx GroupCotinga Pharmaceuticals Inc. (COT.V)Pacgen Life Science Co. (PBS.V)Port Erin Biopharma InvestmentsMedifocus Inc. (MFS.V)
SymbolLON:SALVCVE:COTCVE:PBSLON:PEBICVE:MFS
Price Information
Current PriceN/AC$0.04C$0.03GBX 4.50C$0.01
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score0.90.50.60.60.5
Analysis Score0.00.00.00.00.0
Community Score2.82.72.92.52.5
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score1.90.00.00.60.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market Cap£1.65 millionC$1.54 millionC$1.30 million£1.04 millionC$925,000.00
BetaN/AN/AN/AN/AN/A
Average Volume50,75820,28163,60143,123317,764
Sales & Book Value
Annual Revenue£64.50 millionN/AC$302,079.00£28,300.00C$2.23 million
Price / Sales0.00N/A6.4436.880.83
CashflowN/AC$0.00 per shareC$0.00 per shareGBX 8.20 per shareC$0.00 per share
Price / Cash3.5017.5030.000.5510.00
Book ValueGBX 15.40 per shareC($0.18) per shareC$0.00 per shareGBX 8.10 per shareC($0.07) per share
Price / Book0.00N/A-30.000.01-0.15
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSGBX 168.80C($0.12)C($0.01)GBX (0.70)C($0.01)
Trailing P/E Ratio0.03N/AN/AN/AN/A
Forward P/E RatioN/A∞∞∞∞
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AC$0.24C$0.09N/AN/A
Dividend YieldN/A685.71%300.00%N/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/A N/A N/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio14.50%N/A78.48%N/AN/A
Current Ratio1.89%0.05%0.81%59.77%0.04%
Quick Ratio1.89%0.01%0.40%59.77%0.03%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees2N/AN/AN/A7
Shares Outstanding36.70 million21.99 million64.82 million23.20 million184.98 million
Next Earnings DateN/A4/21/2021 (Estimated)N/AN/AN/A
OptionableNot OptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
MFS.V - Medifocus Inc. Profile | ReutersMFS.V - Medifocus Inc. Profile | Reuters
reuters.com - November 10 at 2:47 PM
IIROC Trading Halt - MFSIIROC Trading Halt - MFS
finance.yahoo.com - September 9 at 3:18 PM
Medifocus Inc. Announces Resignation of Chief Financial OfficerMedifocus Inc. Announces Resignation of Chief Financial Officer
wallstreet-online.de - August 21 at 7:13 PM
Medifocus Inc. Announces Delayed Filing of Annual Disclosure Documents Pursuant to OSC Instrument 51-502Medifocus Inc. Announces Delayed Filing of Annual Disclosure Documents Pursuant to OSC Instrument 51-502
business.financialpost.com - July 24 at 5:11 PM
Medifocus, Inc. Announces Global Market Expansion with Prolieve® Performed and Reimbursed by Insurance Carriers in Hong KongMedifocus, Inc. Announces Global Market Expansion with Prolieve® Performed and Reimbursed by Insurance Carriers in Hong Kong
globenewswire.com - January 3 at 10:59 AM
Medifocus, Inc. Announces Recent Publication Highlighting Its Focal Therapy for Prostate and Breast Cancer Treatment InitiativesMedifocus, Inc. Announces Recent Publication Highlighting Its Focal Therapy for Prostate and Breast Cancer Treatment Initiatives
globenewswire.com - December 27 at 11:02 AM
DateCompanyBrokerageAction
12/11/2018SalvaRx GroupNorthland SecuritiesReiterated Rating
(Data available from 4/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.